Appendix 1.

Timeline of events pertaining to the use of gabapentin for bipolar disorder

Month and Year	Event
May, 1977	U.S. Patent granted to Warner-Lambert for gabapentin
December, 1993	Gabapentin is FDA-approved for adjunctive treatment of partial complex seizures in individuals over 12 years old
June, 1995	Depakote, an anticonvulsant drug, is approved to treat bipolar mania
August, 1996	Lawsuit filed by a former Parke-Davis employee against Warner-Lambert for illegal marketing of gabapentin for off-label uses
December, 1999	Seal on above lawsuit is lifted and litigation resumes.
June, 2000	Pfizer acquires Warner-Lambert and its marketing division Parke-Davis
Sept, 2000	Publication of 1st RCT that showed that gabapentin had no efficacy in the treatment of BPD
October, 2000	Gabapentin is FDA-approved for adjunctive treatment of partial seizures in patients ages 3–12 years old.
December, 2000	Publication of 2nd RCT that showed that gabapentin had no efficacy in the treatment of BPD
May, 2002	Gabapentin is FDA-approved for treatment of postherpetic neuralgia in adults.
May, 2004	Pfizer agrees to a $430 million settlement for Warner-Lambert’s promotion of gabapentin for uses not approved by the FDA
July 1, 2004	Florida Medicaid institutes a prior authorization program restricting gabapentin use to FDA approved indications